Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6499
    -0.0001 (-0.02%)
     

  • OIL

    82.82
    +0.01 (+0.01%)
     

  • GOLD

    2,328.50
    -9.90 (-0.42%)
     

  • Bitcoin AUD

    98,933.83
    -3,279.27 (-3.21%)
     

  • CMC Crypto 200

    1,385.96
    -38.14 (-2.68%)
     

  • AUD/EUR

    0.6071
    +0.0001 (+0.01%)
     

  • AUD/NZD

    1.0946
    +0.0004 (+0.04%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference

OliX Pharmaceuticals
·2-min read

SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present new data across its pipeline at the 2021 Oligonucleotide Therapeutics Society Virtual Conference, being held virtually September 26-29, 2021.

Key data include preclinical study results for its investigational therapeutic targeting hepatitis B virus (HBV) and OLX702A, an investigational RNAi therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). OliX previously announced that OLX702A reversed tissue damage in the liver in a mouse model of NASH.

OliX will also present an overview of its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A/D for age-related macular degeneration and subretinal fibrosis. The Company expects to initiate clinical trials for OLX104C and OLX301A/D in 2022.

Titles for the pre-recorded poster presentations are below:

ADVERTISEMENT

  • GalNAc-conjugated RNAi Therapeutics by OliX Pharmaceuticals (2021-P-236-OTS)

  • Development of Cell-penetrating Asymmetric siRNA Therapeutics Targeting Skin Diseases, Hypertrophic Scar and Androgenetic Alopecia

  • Nonclinical Development of Novel Cell-penetrating Asymmetric Small Interfering RNA Targeting Genes for Advanced Age-related Macular Degeneration (2021-P242-OTS)

  • RIG-I-mediated Innate Immune Stimulation by Chemically Synthesized Long Double-stranded RNAs is Structure- and Sequence-dependent (2021-P-224-OTS)

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com/eng

Media Contact:

Jon Yu
Westwicke/ICR PR
Phone: +1.475.395.5375
jon.yu@westwicke.com